SCHEMBL1969579

SCHEMBL1969579

O=C(OCc1ccccc1)[C@H]1CC[C@H](n2cnnn2)CC1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
STS P08842 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
FABP7 O15540 1/20 0.41
FABP5 Q01469 1/20 0.41
CYP2C19 P33261 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 2/20 0.40
LMNA P02545 1/20 0.39
PKM P14618 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
NAMPT P43490 1/20 0.39
PIK3CA P42336 2/20 0.39
MTOR P42345 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1969580 1.00 SMN1; SMN2 (0.42) SMN1; SMN2NPC1RAB9ASTSALDH1A1
SCHEMBL30151694 0.82 ALDH1A1 (0.59) ALDH1A1GAATSHR
SCHEMBL4947705 0.82 SMN1; SMN2 (0.46) SMN1; SMN2NPC1RAB9ASTSALDH1A1
SCHEMBL4947712 0.82 SMN1; SMN2 (0.46) SMN1; SMN2NPC1RAB9ASTSALDH1A1
SCHEMBL15018080 0.82 SMN1; SMN2 (0.60) SMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL10917021 0.80 FABP7 (0.58) SMN1; SMN2NPC1RAB9AALDH1A1GAA
SCHEMBL280126 0.80 FABP7 (0.58) SMN1; SMN2NPC1RAB9AALDH1A1GAA
SCHEMBL6666657 0.80 FABP7 (0.58) SMN1; SMN2NPC1RAB9AALDH1A1GAA
Hydrochloric Acid SCHEMBL27944947 0.78 FABP7 (0.57) SMN1; SMN2NPC1RAB9AALDH1A1GAA
Hydrochloric Acid SCHEMBL27765522 0.78 FABP7 (0.57) SMN1; SMN2NPC1RAB9AALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-RE48334-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-12-01 US disclosed
EP-2336105-B9 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL (JP) 2014-09-17 EP disclosed
EP-2336105-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL (JP) 2014-02-12 EP disclosed
US-8592454-B2 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-11-26 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
EP-2336105-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME Takeda Pharmaceutical Company Limited (JP) 2011-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME NTSR2, BDKRB1, AVPR1B SMN1; SMN2 1248/4885NPC1 1587/4885RAB9A 2851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.